Loomis, Sayles & Company
ASND icon

Loomis, Sayles & Company’s Ascendis Pharma A/S ASND Stock Holding History

Loomis, Sayles & Company’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.1M Sell
78,941
-1,464
-2% -$342K 0.03% 248
2026
Q1 		$18.4M Sell
80,405
-31,835
-28% -$7.14M 0.02% 248
2025
Q4 		$23.9M Sell
112,240
-41,165
-27% -$8.5M 0.03% 213
2025
Q3 		$30.5M Buy
153,405
+4,908
+3% +$915K 0.04% 170
2025
Q2 		$25.6M Sell
148,497
-26,416
-15% -$4.3M 0.03% 197
2025
Q1 		$27.3M Sell
174,913
-3,986
-2% -$569K 0.04% 193
2024
Q4 		$24.6M Sell
178,899
-5,724
-3% -$753K 0.03% 222
2024
Q3 		$27.6M Buy
184,623
+63,029
+52% +$8.51M 0.04% 213
2024
Q2 		$16.6M Buy
+121,594
New +$16.5M 0.02% 280
2021
Q3 		– Sell
-179,446
Closed -$23.6M – 888
2021
Q2 		$23.6M Buy
179,446
+6,862
+4% +$914K 0.03% 284
2021
Q1 		$22.2M Buy
172,584
+14,948
+9% +$2.27M 0.03% 273
2020
Q4 		$26.3M Buy
157,636
+32,626
+26% +$5.4M 0.03% 229
2020
Q3 		$19.3M Sell
125,010
-1,380
-1% -$198K 0.03% 240
2020
Q2 		$18.7M Buy
126,390
+9,795
+8% +$1.34M 0.03% 227
2020
Q1 		$13.1M Sell
116,595
-1,286
-1% -$167K 0.03% 246
2019
Q4 		$16.4M Sell
117,881
-8,986
-7% -$998K 0.03% 256
2019
Q3 		$12.2M Buy
126,867
+25,664
+25% +$2.86M 0.02% 302
2019
Q2 		$11.7M Sell
101,203
-6,141
-6% -$735K 0.02% 314
2019
Q1 		$12.6M Sell
107,344
-359
-0.3% -$31.4K 0.02% 307
2018
Q4 		$6.75M Buy
107,703
+19,648
+22% +$1.23M 0.02% 381
2018
Q3 		$6.24M Buy
+88,055
New +$6.06M 0.01% 452

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Loomis, Sayles & Company's ASND Position: Q2 2026 in Review

Loomis, Sayles & Company reduced its Ascendis Pharma A/S (ASND) stake by 1.8% in Q2 2026, selling an estimated $342K and leaving 78,941 shares worth $21.1M. The position accounts for 0.03% of the portfolio, ranked #248.

Loomis, Sayles & Company first reported a position in ASND in Q3 2018 and has held it in 21 quarters since. The position peaked at $30.5M in Q3 2025. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

  • Loomis, Sayles & Company held 78,941 shares of Ascendis Pharma A/S worth $21.1M as of Q2 2026.
  • Loomis, Sayles & Company sold 1,464 Ascendis Pharma A/S shares in Q2 2026, an estimated $342K.
  • Ascendis Pharma A/S made up 0.03% of Loomis, Sayles & Company's portfolio in Q2 2026, its #248 holding.
  • Loomis, Sayles & Company first reported a position in Ascendis Pharma A/S in Q3 2018 and has held it in 21 quarters since.
  • Loomis, Sayles & Company's Ascendis Pharma A/S position peaked at $30.5M in Q3 2025.
  • 312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Loomis, Sayles & Company's 13F filing for Q2 2026, filed 14 Aug 2026.